Vaxcyte Inc Ordinary Shares PCVX
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Vaxcyte Announces Closing of $1.15 Billion Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes, Including Full Exercise of Underwriters’ Options to Purchase Additional Shares and Convertible Senior Notes
-
Vaxcyte Announces Pricing of Concurrent Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
-
Vaxcyte Announces Commencement of Proposed Public Offerings of Common Stock, Pre-Funded Warrants and Convertible Senior Notes
-
Vaxcyte Reports Bacterial-Infection Vaccine Met Primary Endpoints in Phase 3 Trial
-
Vaxcyte Reports Positive Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
-
Vaxcyte to Host Webcast and Conference Call to Present Topline Data from OPUS-1, the Pivotal Adult Phase 3 Trial of VAX-31, the Company’s 31-Valent Pneumococcal Conjugate Vaccine Candidate
-
Vaxcyte Appoints Chief Medical Officer and Chief Legal Officer; Narrows Guidance for Expected VAX-31 OPUS-1 Topline Data
-
Vaxcyte to Participate in Upcoming Investor Conferences
Trading Information
- Previous Close Price
- $63.23
- Day Range
- $61.56–64.58
- 52-Week Range
- $39.87–90.75
- Bid/Ask
- $60.18 / $62.82
- Shares Outstanding
- 157.39M
- Market Cap
- $9.89B
- Volume/Avg
- 3M / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Core
- Total Number of Employees
- 507
- Website
- https://www.vaxcyte.com
Valuation
|
Metric
|
PCVX
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 3.30 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
PCVX
|
|---|---|
Quick Ratio | 5.48 |
Current Ratio | 5.72 |
Interest Coverage | — |
Quick Ratio
PCVX
Profitability
|
Metric
|
PCVX
|
|---|---|
Return on Assets (Normalized) | −28.46% |
Return on Equity (Normalized) | −31.55% |
Return on Invested Capital (Normalized) | −34.07% |
Return on Assets
PCVX
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?J?rYP | LOCK|>?V^ | $136B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|>?^Lbjw | LOCK|H@rJ | $84B | |||
| Moderna Inc
MRNA
| LOCK|BV>Cp& | LOCK|gq& | $81B | |||
| argenx SE ADR
ARGX
| LOCK|DY!?Dh | LOCK|yX | $55B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%D%TkQw | LOCK|S!& | $44B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|qz<LWr^ | LOCK|f!p&# | $30B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|sPBKTx> | LOCK|G#@G | $28B | |||
| Incyte Corp
INCY
| LOCK|%yY?s&# | LOCK|?s? | $24B | |||
| BioNTech SE ADR
BNTX
| LOCK|@$?$Zv | LOCK|^&P | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|&^cfVk% | LOCK|VL@ | $14B |
United States